We are live on ! Find out more
MACM

March Altus Capital Management Portfolio holdings

AUM $16M
1-Year Est. Return 18.92%
This Fund
S&P 500
This Quarter Est. Return
+13.23%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$17.2M
AUM Growth
+$1.3M
Cap. Flow
-$424K
Cap. Flow %
-2.46%
Top 10 Hldgs %
72.09%
Holding
23
New
8
Increased
3
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$669K
2
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$548K
3
ALXN
Alexion Pharmaceuticals
ALXN
+$392K
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$372K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$364K

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$974K
2
LH icon
Labcorp
LH
+$723K
3
INCY icon
Incyte
INCY
+$710K
4
CYNO
Cynosure, Inc. Class A
CYNO
+$642K
5
HUM icon
Humana
HUM
+$472K

Sector Composition

Rank Sector Weight
1 Healthcare 85.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UHS icon
1
Universal Health Services
UHS
$9.88B
$2.08M 12.11%
14,663
-790
-5% -$98.9K
UTHR icon
2
United Therapeutics
UTHR
$26.2B
$1.74M 10.12%
10,009
-799
-7% -$144K
LLY icon
3
Eli Lilly
LLY
$1.03T
$1.31M 7.64%
15,738
+1,546
+11% +$118K
DXCM icon
4
DexCom
DXCM
$28.8B
$1.24M 7.21%
62,016
-3,312
-5% -$58.2K
REGN icon
5
Regeneron Pharmaceuticals
REGN
$77.4B
$1.17M 6.8%
2,294
-98
-4% -$47.8K
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$1.07M 6.25%
5,949
+2,269
+62% +$392K
THOR
7
DELISTED
THORATEC CORPORATION
THOR
$1.05M 6.09%
23,486
-1,279
-5% -$56K
CYNO
8
DELISTED
Cynosure, Inc. Class A
CYNO
$983K 5.71%
25,475
-18,254
-42% -$642K
MNK
9
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$963K 5.6%
8,177
-363
-4% -$44.8K
CI icon
10
Cigna
CI
$76.1B
$784K 4.56%
+4,842
New +$669K
HUM icon
11
Humana
HUM
$44B
$739K 4.3%
3,862
-2,541
-40% -$472K
ZTS icon
12
Zoetis
ZTS
$31.9B
$721K 4.19%
14,956
+209
+1% +$9.98K
COR icon
13
Cencora
COR
$60.7B
$713K 4.14%
6,707
-10
-0.1% -$1.13K
ZLTQ
14
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$535K 3.11%
+18,165
New +$548K
RCPT
15
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$428K 2.49%
+2,251
New +$372K
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
$424K 2.46%
+8,768
New +$362K
NBIX icon
17
Neurocrine Biosciences
NBIX
$18.7B
$410K 2.38%
+8,593
New +$364K
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.56B
$338K 1.96%
+3,299
New +$256K
CPRX
19
DELISTED
Catalyst Pharmaceutical
CPRX
$334K 1.94%
+80,890
New +$322K
AGEN
20
Agenus
AGEN
$329M
$160K 0.93%
+943
New +$134K
INCY icon
21
Incyte
INCY
$24.9B
– –
-7,742
Closed -$710K
LH icon
22
Labcorp
LH
$25.9B
– –
-6,676
Closed -$723K
MDCO
23
DELISTED
Medicines Co
MDCO
– –
-34,744
Closed -$974K

Similar funds

IC
IKOS CIF Limassol, Cyprus $16.7M AUM 0.4% 1-Year Est. Return
PA
Para Advisors New York $17.5M AUM 3.99% 1-Year Est. Return
GMIM
General Motors Investment Management New York $20.3M AUM 55.51% 1-Year Est. Return
JHWCP
J.H. Whitney Capital Partners New Canaan, Connecticut $11.5M AUM 86.36% 1-Year Est. Return
SMPIAI
Spark Management Partners III (AIV I) Boston, Massachusetts $10.1M AUM 12.29% 1-Year Est. Return
NCMG
NCM Capital Management Group Durham, North Carolina $8.24M AUM 11.99% 1-Year Est. Return
CAD
Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return
GPI
Georgian Partners I Toronto, Ontario, Canada $25.3M AUM 21.88% 1-Year Est. Return

March Altus Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, March Altus Capital Management held 23 positions worth $17.2M, up 8.2% from $15.9M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

March Altus Capital Management's Q2 2015 filing shows 8 new, 3 increased, 9 reduced and 3 closed positions. Its largest new stake was Cigna: 4,842 shares worth $784K. The largest sale was Medicines Co, an estimated $974K.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 79% a quarter earlier.

  • March Altus Capital Management's largest Q2 2015 buy was Cigna: 4,842 shares worth $784K.
  • March Altus Capital Management added most to Alexion Pharmaceuticals in Q2 2015, an estimated $392K increase.
  • March Altus Capital Management's biggest Q2 2015 reduction was Cynosure, Inc. Class A, cutting an estimated $642K.
  • March Altus Capital Management fully exited Medicines Co in Q2 2015, selling an estimated $974K.
  • March Altus Capital Management's ten largest holdings make up 72% of its $17.2M portfolio in Q2 2015.
  • March Altus Capital Management opened 8 new positions and closed 3 in Q2 2015.
  • March Altus Capital Management's portfolio value rose 8.2% quarter-over-quarter to $17.2M.

Based on March Altus Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.